ASH2014 - Clinical Care Options (free to join) capsule update on...
Venetoclax (ABT-199)Plus Rituximab Well Tolerated With Promising Activity in Patients With Relapsed/Refractory CLL
Venetoclax/rituximab achieved ORR of 88% in early investigation and 400 mg identified as the recommended dose for future studies.
clinicaloptions.com/Oncolog...
Recent update on ABT-199 (monotherapy) from ASCO 2014: healthunlocked.com/cllsuppo...
Neil
Photo: Jacky Winter, with thanks to Jay as usual for the identification